273 related articles for article (PubMed ID: 31834371)
21. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Palasamudram S; Zak M; Whitney R; McCoy B; Bouffet E; Taylor M; Shroff M; Bartels U
J Neurooncol; 2020 May; 147(3):731-736. PubMed ID: 32285309
[TBL] [Abstract][Full Text] [Related]
22. Subependymal giant cell astrocytoma: a lesion with activated mTOR pathway and constant expression of glutamine synthetase.
Buccoliero AM; Caporalini C; Giordano F; Mussa F; Scagnet M; Moscardi S; Baroni G; Genitori L; Taddei GL
Clin Neuropathol; 2016; 35(5):295-301. PubMed ID: 27390104
[TBL] [Abstract][Full Text] [Related]
23. Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients.
Kotulska K; Borkowska J; Roszkowski M; Mandera M; Daszkiewicz P; Drabik K; Jurkiewicz E; Larysz-Brysz M; Nowak K; Grajkowska W; Domańska-Pakieła D; Jóźwiak S
Pediatr Neurol; 2014 Apr; 50(4):307-12. PubMed ID: 24507694
[TBL] [Abstract][Full Text] [Related]
24. Isolated subependymal giant cell astrocytoma (SEGA) in the absence of clinical tuberous sclerosis: two case reports and literature review.
Cobourn KD; Chesney KM; Mueller K; Fayed I; Tsering D; Keating RF
Childs Nerv Syst; 2024 Jan; 40(1):73-78. PubMed ID: 37658938
[TBL] [Abstract][Full Text] [Related]
25. The level of microRNA 21 is upregulated by rapamycin in serum of tuberous sclerosis complex patients and subependymal giant cell astrocytoma (SEGA)-derived cell cultures.
Kuzniewska B; Sadowski K; Urbanska K; Urbanska M; Kotulska K; Liszewska E; Grajkowska W; Jóźwiak S; Dziembowska M
Folia Neuropathol; 2018; 56(3):167-174. PubMed ID: 30509037
[TBL] [Abstract][Full Text] [Related]
26. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Pole JD; Bouffet E; Taylor MD; Bartels U
Pediatr Blood Cancer; 2015 Oct; 62(10):1754-60. PubMed ID: 25929843
[TBL] [Abstract][Full Text] [Related]
27. [Subependymal giant cell astrocytoma associated with tuberous sclerosis complex - pharmacological treatment using mTOR inhibitors].
Zitterbart K
Klin Onkol; 2014; 27(6):401-5. PubMed ID: 25493579
[TBL] [Abstract][Full Text] [Related]
28. Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex.
Ess KC; Kamp CA; Tu BP; Gutmann DH
Neurology; 2005 Apr; 64(8):1446-9. PubMed ID: 15851742
[TBL] [Abstract][Full Text] [Related]
29. Magnetic resonance imaging diagnosis of subependymal giant cell astrocytomas in follow-up of children with tuberous sclerosis complex: should we always use contrast enhancement?
Gaillard AL; Crombé A; Jecko V; Bessou P; Havez M; Pédespan JM; Van Gils J; Chateil JF
Pediatr Radiol; 2020 Sep; 50(10):1397-1408. PubMed ID: 32671416
[TBL] [Abstract][Full Text] [Related]
30. Targeting the EGFR pathway: An alternative strategy for the treatment of tuberous sclerosis complex?
Schachenhofer J; Gruber VE; Fehrer SV; Haider C; Glatter S; Liszewska E; Höftberger R; Aronica E; Rössler K; Jaworski J; Scholl T; Feucht M
Neuropathol Appl Neurobiol; 2024 Apr; 50(2):e12974. PubMed ID: 38562027
[TBL] [Abstract][Full Text] [Related]
31. Tuberous sclerosis complex neuropathology requires glutamate-cysteine ligase.
Malik AR; Liszewska E; Skalecka A; Urbanska M; Iyer AM; Swiech LJ; Perycz M; Parobczak K; Pietruszka P; Zarebska MM; Macias M; Kotulska K; Borkowska J; Grajkowska W; Tyburczy ME; Jozwiak S; Kwiatkowski DJ; Aronica E; Jaworski J
Acta Neuropathol Commun; 2015 Jul; 3():48. PubMed ID: 26220190
[TBL] [Abstract][Full Text] [Related]
32. A case of solitary subependymal giant cell astrocytoma with histopathological anaplasia and TSC2 gene alteration.
Suzuki M; Kondo A; Ogino I; Akiyama O; Fujita N; Shimizu Y; Arai H
Childs Nerv Syst; 2021 Apr; 37(4):1357-1362. PubMed ID: 32725466
[TBL] [Abstract][Full Text] [Related]
33. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Anak O; Niolat J; Jozwiak S
Lancet Oncol; 2014 Dec; 15(13):1513-1520. PubMed ID: 25456370
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-34a activation in tuberous sclerosis complex during early brain development may lead to impaired corticogenesis.
Korotkov A; Sim NS; Luinenburg MJ; Anink JJ; van Scheppingen J; Zimmer TS; Bongaarts A; Broekaart DWM; Mijnsbergen C; Jansen FE; Van Hecke W; Spliet WGM; van Rijen PC; Feucht M; Hainfellner JA; Kršek P; Zamecnik J; Crino PB; Kotulska K; Lagae L; Jansen AC; Kwiatkowski DJ; Jozwiak S; Curatolo P; Mühlebner A; Lee JH; Mills JD; van Vliet EA; Aronica E
Neuropathol Appl Neurobiol; 2021 Oct; 47(6):796-811. PubMed ID: 33942341
[TBL] [Abstract][Full Text] [Related]
35. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations.
Jóźwiak S; Nabbout R; Curatolo P;
Eur J Paediatr Neurol; 2013 Jul; 17(4):348-52. PubMed ID: 23391693
[TBL] [Abstract][Full Text] [Related]
36. Association between the growth rate of subependymal giant cell astrocytoma and age in patients with tuberous sclerosis complex.
Tsai JD; Wei CC; Tsao TF; Hsiao YP; Tsai HJ; Yang SH; Tsai ML; Sheu JN
Childs Nerv Syst; 2016 Jan; 32(1):89-95. PubMed ID: 26552385
[TBL] [Abstract][Full Text] [Related]
37. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
[TBL] [Abstract][Full Text] [Related]
38. Subependymal Giant Cell Astrocytomas in Tuberous Sclerosis Complex-Current Views on Their Pathogenesis and Management.
Gao C; Zabielska B; Jiao F; Mei D; Wang X; Kotulska K; Jozwiak S
J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769603
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
40. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.
Cheng S; Hawkins C; Taylor MD; Bartels U
Pediatr Neurol; 2015 Sep; 53(3):238-242.e1. PubMed ID: 26173783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
